Immune evasion before tumour invasion in early lung squamous carcinogenesis.
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
27
11
2018
accepted:
24
05
2019
pubmed:
28
6
2019
medline:
24
3
2020
entrez:
28
6
2019
Statut:
ppublish
Résumé
Early detection and treatment are critical for improving the outcome of patients with cancer
Identifiants
pubmed: 31243362
doi: 10.1038/s41586-019-1330-0
pii: 10.1038/s41586-019-1330-0
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
570-575Références
Goldberg, S. W., Mulshine, J. L., Hagstrom, D. & Pyenson, B. S. An actuarial approach to comparing early stage and late stage lung cancer mortality and survival. Popul. Health Manag. 13, 33–46 (2010).
pubmed: 20158322
Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782–795 (2013).
pubmed: 24138885
Mlecnik, B. et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J. Clin. Oncol. 29, 610–618 (2011).
pubmed: 21245428
Herbst, R. S., Morgensztern, D. & Boshoff, C. The biology and management of non-small cell lung cancer. Nature 553, 446–454 (2018).
pubmed: 29364287
De Koning, H., Van Der Aalst, C., Ten Haaf, K. & Oudkerk, M. PL02.05 effects of volume CT lung cancer screening: mortality results of the NELSON randomised-controlled population based trial. J. Thorac. Oncol. 13, S185 (2018).
Umar, A., Dunn, B. K. & Greenwald, P. Future directions in cancer prevention. Nat. Rev. Cancer 12, 835–848 (2012).
pubmed: 23151603
Kensler, T. W. et al. Transforming cancer prevention through precision medicine and immune-oncology. Cancer Prev. Res. 9, 2–10 (2016).
Slaughter, D. P., Southwick, H. W. & Smejkal, W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6, 963–968 (1953).
pubmed: 13094644
Kerr, K. M. Pulmonary preinvasive neoplasia. J. Clin. Pathol. 54, 257–271 (2001).
pubmed: 11304841
pmcid: 1731391
Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).
pubmed: 17008531
Galon, J., Angell, H. K., Bedognetti, D. & Marincola, F. M. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39, 11–26 (2013).
pubmed: 23890060
Pagès, F. et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391, 2128–2139 (2018).
Pagès, F. et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J. Clin. Oncol. 27, 5944–5951 (2009).
pubmed: 19858404
Fridman, W. H., Pagès, F., Sautès-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298–306 (2012).
pubmed: 22419253
Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938–945 (2015).
pubmed: 26193342
pmcid: 4852857
Teixeira, V. H. et al. Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions. Nat. Med. 25, 517–525 (2019).
pubmed: 30664780
Wu, S., Powers, S., Zhu, W. & Hannun, Y. A. Substantial contribution of extrinsic risk factors to cancer development. Nature 529, 43–47 (2016).
pubmed: 26675728
Angelova, M. et al. Evolution of metastases in space and time under immune selection. Cell 175, 751–765 (2018).
pubmed: 30318143
Mlecnik, B. et al. The tumor microenvironment and immunoscore are critical determinants of dissemination to distant metastasis. Sci. Transl. Med. 8, 327ra26 (2016).
pubmed: 26912905
Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197–218 (2019).
pubmed: 30610226
Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078–2092 (2018).
pubmed: 29658856
Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).
Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015).
pubmed: 26028407
pmcid: 4681400
Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540–1550 (2016).
Antonia, S. J. et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N. Engl. J. Med. 379, 2342–2350 (2018).
pubmed: 30280658
Eggermont, A. M. M. et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N. Engl. J. Med. 378, 1789–1801 (2018).
pubmed: 29658430
Forde, P. M. et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl. J. Med. 378, 1976–1986 (2018).
pubmed: 29658848
pmcid: 6223617
Mascaux, C. et al. Evolution of microRNA expression during human bronchial squamous carcinogenesis. Eur. Respir. J. 33, 352–359 (2009).
pubmed: 19010987
Bota, S. et al. Follow-up of bronchial precancerous lesions and carcinoma in situ using fluorescence endoscopy. Am. J. Respir. Crit. Care Med. 164, 1688–1693 (2001).
pubmed: 11719311
Breuer, R. H. et al. The natural course of preneoplastic lesions in bronchial epithelium. Clin. Cancer Res. 11, 537–543 (2005).
pubmed: 15701838